Overcoming barriers in HPV vaccination and screening programs

A. Vorsters* (Corresponding Author), M. Arbyn, M. Baay, X. Bosch, S. de Sanjose, S. Hanley, E. Karafillakis, P. L. Lopalco, K. G. Pollock, J. Yarwood, P. Van Damme

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

36 Citations (Scopus)


The Human Papillomavirus Prevention and Control Board brought together experts to discuss optimizing HPV vaccination and screening programs. Board members reviewed the safety profile of licensed HPV vaccines based on clinical and post-marketing data, reaching a consensus that current safety data is reassuring. Successful vaccination programs used well-coordinated communication campaigns, integrating (social) media to spread awareness. Communication of evidence supporting vaccine effectiveness had beneficial effects on the perception of the vaccine. However, anti-vaccination campaigns have threatened existing programs in many countries. Measurement and monitoring of HPV vaccine confidence over time could help understand the nature and scale of waning confidence, define issues and intervene appropriately using context-specific evidence-based strategies. Finally, a broad group of stakeholders, such as teachers, health care providers and the media should also be provided with accurate information and training to help support prevention efforts through enhanced understanding of the risks and benefits of vaccination. Similarly, while cervical cancer screening through population-based programs is highly effective, barriers to screening exist: awareness in countries with population-based screening programs, access for vulnerable populations, and access and affordability in low- and middle-income countries. Integration of primary and secondary prevention has the potential to accelerate the decrease in cervical cancer incidence.
Original languageEnglish
Pages (from-to)45-53
Number of pages9
JournalPapillomavirus Res
Early online date28 Jul 2017
Publication statusPublished - 1 Dec 2017

Bibliographical note

The HPV Prevention and Control Board is supported by unrestricted grants from the vaccine industry (GlaxoSmithKline Biologicals, Merck).

SdS receives partial support from AGAUR, Generalitat de Catalunya (2014 SGR 756)

We would like to thank all speakers and participants who contributed to the success of the meeting. We are grateful to Lisa Lindsay (P95, Epidemiology and Pharmacovigilance Consulting and Services) for careful review of the manuscript.


  • Female
  • Humans
  • *Early Detection of Cancer
  • Mass Screening
  • Immunization Programs
  • *(max 6) Human papillomavirus
  • *Barriers
  • *Screening
  • *Vaccine
  • *Vaccine confidence
  • Communication
  • Health Personnel
  • Papillomaviridae/immunology
  • Papillomavirus Infections/epidemiology/*prevention & control
  • Papillomavirus Vaccines/administration & dosage/*adverse effects/immunology
  • Vaccination/adverse effects/psychology/*statistics & numerical data


Dive into the research topics of 'Overcoming barriers in HPV vaccination and screening programs'. Together they form a unique fingerprint.

Cite this